Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 201 to 210 of 797

TitleReference numberPublishedLast updated
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitisTA825
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)TA826
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)TA822
Dexamethasone intravitreal implant for treating diabetic macular oedemaTA824
Brolucizumab for treating diabetic macular oedemaTA820
Avalglucosidase alfa for treating Pompe diseaseTA821
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesotheliomaTA818
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816

Results per page

  1. 10
  2. 25
  3. 50
  4. All